CTLA-4 and PD-1 modulate different aspects of the T-cell response: A, CTLA-4 is upregulated after antigen-specific activation of a naïve or memory T cell.

Slides:

Advertisements

Similar presentations

José Pedro Lopes Exhausted CD3 CD8 TCR TIM3 1B11 LAG3 Generated in chronic antigen- mediated TCR stimulation. Express inhibitory receptors and lack effector.

Advertisements

Immunological tolerance and immune regulation -- 1

Activation of T Lymphocytes

Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.

Suzanne L. Topalian, Charles G. Drake, Drew M. Pardoll Cancer Cell

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

Adverse Renal Effects of Immune Checkpoint Inhibitors:

Figure 1 Key elements of cancer-related inflammation

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Discussion Outline Cells of the Immune System.

IL-22 Gets to the Stem of Colorectal Cancer

Heating is a multifunctional adjuvant that affects tumor microenvironment through several intrinsic and extrinsic mechanisms, which could enhance immunotherapy.

Differentiation and Functions of CD8+ Effector T Cells

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Unmasking Pancreatic Cancer: Epitope Spreading After Single Antigen Chimeric Antigen Receptor T-Cell Therapy in a Human Phase I Trial Max Heckler, Stephanie.

Co-Receptors: Function

Schematic diagram outlining the antitumor activity and abscopal effect in combining checkpoint inhibitors with radiation-induced immune response. Schematic.

Colorectal cancer vaccines: Principles, results, and perspectives

Putting the work of B and T cells together

Nat. Rev. Clin. Oncol. doi: /nrclinonc

PD-1 and LAG-3 expression in MSI and MSS colorectal cancer specimens.

Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.

Hiding in Plain Sight: How Cancer Evades the Immune System

Ana C. Anderson, Nicole Joller, Vijay K. Kuchroo Immunity

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.

Figure 1 The role of CTLA4 and PD1 in T cell activation

Potential mechanisms of therapeutic synergy between epigenetic modulation and PD-1 pathway blockade. Potential mechanisms of therapeutic synergy between.

Immunity to Infectious Diseases

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Low-dose cyclophosphamide (Cy) reduces intratumoral Treg numbers and promotes enhanced T-cell trafficking and activation within the tertiary lymphoid aggregates.

Mechanisms of immune escape in the tumor microenvironment.

IL32 prompts cell activation and cancer-related pathways.

Mechanism of CTLA-4-induced immunosuppression.

Nat. Rev. Endocrinol. doi: /nrendo

Schematic representation of mechanisms leading to the synergy of anti-CD137 and anti–PD-1 immunostimulatory mAbs. Schematic representation of mechanisms.

Figure 3 Underlying mechanisms of TREG cells in atherosclerosis

NICD1 immunohistochemical staining in normal and tumor tissue.

Cell-mediated immunity Regulation of the immune response

Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex;

Releasing the Brakes on Cancer Immunotherapy

Vaccines for Lung Cancer

Mice immunized twice with RRBC showed superior protection to tumor challenge with αGal-positive MC38 colon carcinoma cells compared with mock-immunized.

Geographic colocalization of PD-L1+ tumor cells with infiltrating immune cells in MCC. The predominant pattern of tumor cell PD-L1 expression is at the.

Protein expression profile in a dasatinib-resistant cell line.

Various impediments in the uptake and retention of radiolabeled antibodies in solid tumors and strategies to modulate these biological barriers. Various.

VEGF expression in neoplastic and normal prostate tissue.

Lymphatic vessels, inflammation, and immunity.

MPGES is expressed in epithelial cells in benign and malignant tumors of the colon. mPGES is expressed in epithelial cells in benign and malignant tumors.

Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.

CDN–treated MOC1 tumors demonstrate enhanced activation of innate and antigen-specific adaptive immunity. CDN–treated MOC1 tumors demonstrate enhanced.

(A) Lymph node priming phase: recognition of major histocompatibility complex (MHC) by T-cell receptor (TCR), coactivating CD 28/B7 pathway activation.

PD-L1 is expressed in breast cancer.

Reduced klotho expression in pancreatic cancer.

Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.

PVT1 facilitated gastric cancer progression in a FOXM1-mediated manner

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

A, Selected 4 quantitative imaging features significantly associated with 3 imaging subtypes, including tumor volume, tumor sphericity, tumor homogeneity.

Putative molecular pathways showing how GSK3β regulates the fate of tumor cells (survival, proliferation, or apoptosis) and influences their sensitivity.

Immune escape mechanisms in cancer.

Nanostring analysis of tumors after ILI and after combination limb infusion and ipilimumab. Nanostring analysis of tumors after ILI and after combination.

Blockade of cell cycle at G2-M phase in Bel-7402 cells treated with IG-105. Blockade of cell cycle at G2-M phase in Bel-7402 cells treated with IG-105.

Correlations between APOBEC expression and immune cell markers across 22 cancer types. Correlations between APOBEC expression and immune cell markers across.

Cytokines and cytokine receptors involved in type I immunity in tuberculosis. Cytokines and cytokine receptors involved in type I immunity in tuberculosis.

Venn diagram showing the overlap of PD-L1 overexpression, MSI-NGS–high, and TML-high in all gastrointestinal tumors, with all three markers tested (N =

CD36 expression in tissue adjacent and distal to the tumor.

Stable IL-10: A New Therapeutic that Promotes Tumor Immunity

Phenotyping of T cells. Phenotyping of T cells. Circulating lymphocytes from a tumor-naïve C57BL/6 mice (left column) were compared with those from C57BL/6.

RIL21 and checkpoint blockade restore IFNγ production in Tim-3+PD-1+ intratumoral NK cells from cancer patients. rIL21 and checkpoint blockade restore.

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

Presentation transcript:

CTLA-4 and PD-1 modulate different aspects of the T-cell response: A, CTLA-4 is upregulated after antigen-specific activation of a naïve or memory T cell in lymphatic tissue, leading to decreased effector function (early activation phase). CTLA-4 and PD-1 modulate different aspects of the T-cell response: A, CTLA-4 is upregulated after antigen-specific activation of a naïve or memory T cell in lymphatic tissue, leading to decreased effector function (early activation phase). B, PD-1 is mainly expressed on antigen-experienced memory T cells in peripheral tissues cells. The immune modulation mediated by this pathway ensures protection of tissue from collateral damage during an inflammatory response. Tumor cells use this regulatory mechanism to evade a tumor-directed T-cell response by upregulating the PD-1 ligands B7-H1 and B7-DC. Patrick A. Ott et al. Clin Cancer Res 2013;19:5300-5309 ©2013 by American Association for Cancer Research